Loading...
Loading...
VIRX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.6M |
| Operating I/L | -11.6M |
| Other Income/Expense | 1.2M |
| Interest Income | 0.6M |
| Pretax | -10.3M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -10.5M |
Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for the treatment of virus-associated malignancies. Its lead product candidate, Nana-val, is in Phase II clinical trials for Epstein-Barr virus-positive lymphoma and is also being evaluated for the treatment of various relapsed/refractory Epstein-Barr virus-positive lymphomas, nasopharyngeal carcinoma, and other solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor, and VRx-510, a preclinical-stage PDK-1 inhibitor. Viracta Therapeutics, Inc. is exploring development and collaboration opportunities for its products in various oncology indications.
